Verisk Analytics (VRSK) continues to draw attention after its recent share performance, with the stock up over the past month but down over the past 3 months and over the past year.

At a share price of $174.76, Verisk Analytics has a 1-day share price return of 3.41%, but its year to date share price return is down 20.93%, and the 1-year total shareholder return has fallen 43.10%. This indicates that momentum has been fading over a longer horizon despite the recent bounce.

If you are thinking about where else capital might find stronger trends, this is a good moment to broaden your search with 20 top founder-led companies

So with Verisk Analytics trading at $174.76, sitting at a sizeable discount to analyst price targets and intrinsic estimates, is the recent weakness setting up a buying opportunity, or is the market already pricing in its future growth?

Most Popular Narrative: 150.7% Overvalued

According to the most followed narrative, Verisk Analytics screens as very expensive, with a fair value of $69.70 against the current share price of $174.76.

Verisk Analytics is a regulatory-grade data toll on the US property & casualty insurance industry, monetized through approximately 83% subscription revenue with approximately 92% client retention. VRSK's narrow-moat franchise produces FCF with an unusually high degree of predictability, durable enough to justify a 15× exit multiple at a 35% margin of safety.

Want to see why a business built on long term contracts, portfolio simplification, and a rich exit multiple still lands on a much lower fair value? The tension between predictable cash flows and a discounted required return sits at the center of this narrative, and the full breakdown shows exactly how those moving parts add up to that number.

Result: Fair Value of $69.70 (OVERVALUED)

However, Verisk Analytics still faces risks, including weaker insurance customer budgets and regulatory changes that could pressure subscription pricing or renewal expectations for this data toll model.

Another View on Verisk Analytics: Earnings Multiple vs Fair Ratio

The user narrative calls Verisk Analytics overvalued at $174.76 against a $69.70 fair value, but the market’s own P/E tells a more mixed story. VRSK trades on 25.2x earnings, which is slightly below its peer average of 26.3x, yet above its fair ratio of 22.6x.

That combination, cheaper than peers but richer than the fair ratio, points to a trade off between paying up for a quality franchise and accepting the risk that the market could drift closer to 22.6x. If that happens, would you view it as downside risk or a reset that creates a better entry point?

Next Steps

Curious whether the balance of concerns and potential rewards around Verisk Analytics matches your own read of the story? Given that investors see both risks and positives in this setup, it is worth reviewing the details yourself and weighing the trade off in context with 3 key rewards and 1 important warning sign

Looking for more investment ideas beyond Verisk Analytics?

Do not stop your research with Verisk Analytics. Widen your watchlist with fresh ideas that line up better with your risk tolerance and income goals.

• Target steadier compounding potential by scanning for companies with consistent profitability and prudent leverage using the solid balance sheet and fundamentals stocks screener (48 results).
• Boost your income focus by reviewing companies offering robust cash returns to shareholders through the 7 dividend fortresses.
• Hunt for future leaders before the crowd notices them by checking the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.